
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc. is advancing its pipeline with promising initial Phase 2 results for its fourth-generation EGFR MasterKey inhibitor, BDTX-1535, demonstrating a 36% overall response rate (ORR) among evaluable patients, which improves to 42% when excluding non-target resistance mutations. The company has shown that a significant 74% of patients remained on treatment during the data cut, indicating strong therapeutic potential in relapsed/refractory non-small cell lung cancer (NSCLC) with non-classical EGFR mutations, a market still underserved by current therapies. Additionally, updated data expected in 2025 from dose expansion cohorts may provide further validation of Black Diamond’s innovative approach and enhance the likelihood of favorable regulatory outcomes.
Bears say
Black Diamond Therapeutics Inc faces significant risks that contribute to a negative outlook, including potential negative efficacy data for its key drug candidate, BDTX-1535, and concerns regarding the safety profile of its pipeline treatments. Adjustments to near- to mid-term expense assumptions and commercialization timelines suggest a reduced financial trajectory, with a decrease in price target indicative of these challenges. For the fourth quarter of 2024, the company reported a net loss of $0.28 per share, aligning closely with previous estimates, but projections indicate a deeper full-year net loss of $1.32 for 2025, highlighting ongoing financial struggles.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares